Source link : https://www.newshealth.biz/health-news/iberdomide-promising-for-cutaneous-lupus-in-phase-2-study/
TOPLINE: Patients with cutaneous lupus erythematosus (CLE) experienced improved symptoms with iberdomide, a cereblon modulator, added to standard lupus medications, particularly in subacute and chronic cases. METHODOLOGY: Researchers conducted a randomized phase 2 trial to evaluate the efficacy and safety of iberdomide in 288 patients with CLE (mean age, 45 years; 97% women). Iberdomide is […]
Author : News Health
Publish date : 2024-10-31 10:12:57
Copyright for syndicated content belongs to the linked Source.
